Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Thursday, July 19, 2018 · 456,018,664 Articles · 3+ Million Readers

Nicox: :Opening of U.S. Development Office in Research Triangle Park, North Carolina

Press Release
Nicox: Opening of U.S. Development Office in Research Triangle Park, North Carolina
Company to relocate its growing U.S. development operations to the North Carolina biotech hub in Research Triangle Park Nicox Research Triangle Park team strengthens and expands Nicox's development capabilities, with a focus on advancing NCX 470 and NCX 4251 ...............................................

 

April 25, 2018 - release at 7:30 am CET
Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the opening of its U.S. development office in Research Triangle Park (RTP) in North Carolina.  The decision to relocate from its prior development office in Fort Worth, Texas, and to expand the Company's presence at RTP, is driven by the anticipated progress of NCX 470 for patients with glaucoma and NCX 4251 for patients with blepharitis towards Phase 2 clinical testing.

"The new office opening prominently positions Nicox in a U.S. region known for its culture of leading-edge innovation and diverse scientific and medical expertise," stated Mike Bergamini, PhD, Executive Vice President, Chief Scientific Officer of Nicox.  "We believe our presence in RTP will allow us to better meet the evolving needs of our company, accommodate the expected growth and recruit top talents."

Along with the existing senior R&D management, the team based in RTP currently includes clinical operations, project management, and pharmaceutical and technical operations.  Nicox's new temporary offices have been located in the North Carolina Biotechnology Center since early March and the company expects to secure permanent office space in the RTP area in 2019.  The U.S. development office located in Fort Worth, Texas, is planned to be closed by year end.

"This is an exciting time for Nicox as we expand our U.S. development capabilities and build upon the strong research and development teams located in France and in Italy," said Tomas Navratil, PhD, Vice President, Head of Development at Nicox.  "Together, our teams will continue to drive forward the development programs for our pipeline assets, first of all our two main projects, NCX 470 for patients with glaucoma and NCX 4251 for patients with blepharitis, and hopefully in the near future to transition into development new lead compounds of our NO-donating therapeutics under research.  The opening of our office in the RTP area is an investment in the future of the company and we believe it will be an asset as we progress our entire pipeline."

/EIN News/ --

About Nicox
Nicox S.A. is an international ophthalmology company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health.  By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma.  Nicox currently has two products with approved New Drug Applications, VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024%, exclusively licensed worldwide to Bausch + Lomb, and ZERVIATE(TM) (cetirizine ophthalmic solution), 0.24%, licensed in the U.S. to Eyevance.  In addition, our promising drug-candidate pipeline includes clinical stage assets based both on our proprietary NO-donating research platform and on the repurposing of existing molecules as well as a future generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.  

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage
Bryan, Garnier & Co   Hugo Solvet   Paris, France
Invest Securities   Martial Descoutures   Paris, France
Gilbert Dupont   Damien Choplain   Paris, France

 
 
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Upcoming financial and business conferences
 

May 29  Gilbert Dupont 16th Annual Healthcare Conference  Paris, France
June 4-7  2018 BIO International Convention  Boston, USA
June 27-28  European MidCap Event  Paris, France
October 1-3  Cantor Global Healthcare Conference  New York, USA
Contacts
Nicox
Gavin Spencer,
Executive Vice President, Chief Business Officer
T +33 (0)4 97 24 53 00
communications@nicox.com
Investor Relations
Europe
Nicox
Corporate Communications Department
T +33 (0)4 97 24 53 00
communications@nicox.com

 
Media Relations
United Kingdom
Jonathan Birt
T +44 7860 361 746
jonathan.birt@ymail.com
United States
Argot Partners
Melissa Forst
T +1 (212) 600-1902
melissa@argotpartners.com
France
NewCap
Nicolas Merigeau
T +33 (0)1 44 71 94 98
nicox@newcap.eu
  United States
Argot Partners
David Rosen
T +1 (212) 600-1902
david.rosen@argotpartners.com



  Italy
Argon Healthcare International
Pietro Pierangeli pietro.pierangeli@argonhealthcare.com
Chiara Tettamanti
chiara.tettamanti@argonhealthcare.com
T. +39 02 4951.8300
Disclaimer
The information contained in this document may be modified without prior notice.  This information includes forward-looking statements.  Such forward-looking statements are not guarantees of future performance.  These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2017' filed with the French Autorité des Marchés Financiers (AMF) on March 19, 2018, which is available on Nicox's website (www.nicox.com).
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

Attachment

Powered by EIN News